Huapeng Li

Title: Huapeng Li: Innovator in COVID-19 Vaccine Development

Introduction

Huapeng Li is a notable inventor based in Guangdong, China. He has made significant contributions to the field of biomedical technology, particularly in the development of vaccines against COVID-19. His innovative work has the potential to impact public health on a global scale.

Latest Patents

Huapeng Li holds a patent for a SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus expressing the polypeptide, and a vaccine containing the virus. The patent discloses a SARS-COV-2 antigen polypeptide, along with a method for preparing the recombinant adeno-associated virus. This method involves co-incubating pHelper, pRep2Cap5, and an expression vector, followed by transfecting a cell with polyethyleneimine as a transfection reagent. The resulting recombinant adeno-associated virus is capable of inducing the production of serum neutralizing antibodies against the novel coronavirus, providing a potential immunization strategy for humans against COVID-19.

Career Highlights

Huapeng Li is associated with Hengda Biomedical Technology Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and a focus on addressing pressing health challenges.

Collaborations

Huapeng Li collaborates with notable colleagues, including Chao Zhang and Zhongqiu Liu. Their combined expertise contributes to the success of their projects and enhances the impact of their research.

Conclusion

Huapeng Li's contributions to vaccine development exemplify the critical role of inventors in addressing global health crises. His innovative work in creating a vaccine against COVID-19 showcases the importance of research and collaboration in the fight against infectious diseases.